IP Library Granted Patent US 7,135,282
Granted Patent B1
US 7,135,282 · App. 10/110,511 · Granted Nov 14, 2006

Viral particles with exogenous internal epitopes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,135,282
App. No.
10/110,511
Granted
Nov 14, 2006
Kind
B1
Abstract

The present invention relates to the expression of peptides on viral particles, and more particularly to the expression of peptides on the interior or the viral capsid. Methods are described for modifying viruses so that exogenous epitopes are expressed on the interior of the viral capsid. Viruses that can be modified include (+) stranded RNA viruses, especially plant (+) stranded RNA viruses such as the cowpea mosaic virus. Internal expression is especially useful for the expression of hydrophobic epitopes. The modified viral particles also find use as vaccines and as such are capable of eliciting an immune response.

Claims (10)

1. A compound comprising a chimeric viral particle comprising at least one exogenous peptide inserted in VP-S of cowpea mosaic virus between a tyrosine residue at position 11 and a duplicated tyrosine residue at position 12.

2. A chimeric viral particle according to claim 1 which is capable of assembly in a host cell or tissue.

3. A chimeric virus particle according to claim 1 , wherein the exogenous peptide comprises a cytotoxic T lymphocyte epitope.

4. A chimeric virus particle according to claim 3 wherein the cytotoxic T lymphocyte epitope is derived from the cicumsporozoite protein of Plasmodium berghei.

5. A chimeric virus particle according to claim 4 , wherein the cytotoxic T lymphocyte epitope has the sequence of SEQ ID NO: 7.

6. A chimeric virus particle according to claim 3 , wherein the cytotoxic T lymphocyte epitope is derived from the lymphocytic choriomeningitis virus.

7. A chimeric virus particle according to claim 6 , wherein the cytotoxic T lymphocyte epitope has the sequence of SEQ ID NO: 6.

8. A chimeric virus particle according to claim 6 wherein the cytotoxic T lymphocyte epitope is derived from the nucleocapsid protein of Sendai virus.

9. A chimeric virus particle according to claim 1 , wherein the exogenous epitope is a helper T lymphocyte epitope.

10. A chimeric virus particle according to claim 1 , wherein the exogenous peptide comprises a T lymphocyte epitope.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2010
From: DOW GLOBAL TECHNOLOGIES, INC.; THE DOW CHEMICAL COMPANY
To: PFENEX, INC.
Reel/Frame 023922/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2006
From: HELLENDOORN, KOEN; JONES, TIM
To: THE DOW CHEMICAL COMPANY
Reel/Frame 018353/0682 →